| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10969760 | Vaccine | 2011 | 5 Pages |
Abstract
⺠No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ⺠Efficacy was presumed via a putative serological correlate of protection. ⺠One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ⺠Protection also demonstrated against individual serotypes for 7F and 19A. ⺠50% less IPD in children <2 years from one of the new serotypes since introduction.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Elizabeth Miller, Nicholas J. Andrews, Pauline A. Waight, Mary P.E. Slack, Robert C. George,